Ripston helps B2B clinical trial startups build strategic foundations, achieve product-market fit, balance authenticity with AI adoption, and expand to new markets.
NATICK, Mass., Sept. 30, 2025 – Ripston Marketing Catalyst officially launched today to address a critical gap in the B2B clinical trial market: the need for strategies that balance authenticity with modern execution. With increasing global regulatory expectations, protocol complexity, and investor scrutiny, early-stage vendors are under pressure to deliver value and scale faster than ever before.
“Clinical trial start-ups face unique challenges at every growth stage – from building credibility and securing investors, to validating product-market fit, to driving market penetration,” says Amy Ripston, Founder and CEO of Ripston. “It is absolutely critical to build strategies that are authentic to your company vision, customer realities, and market dynamics. Without that foundation, any execution-based tools and tactics will fall flat.”
Ripston’s philosophy is simple: authenticity fuels results. Lead with Authenticity. Use technology as your strategic partner. Connect customer and market insights across your entire business.
“AI should never replace strategy. It should validate, sharpen, and support your vision,” says Sabrina Fei, Founder, Growth Marketing & Technology Strategist of Ripston. “The real transformative power of AI lies in its ability to automate the mundane, enhance human capabilities, and bring strategic clarity at scale. For clinical trial start-ups, that means less time reacting and more time building what truly moves the business forward.”
Ripston offers tailored service tiers designed specifically for the complexity of clinical trials and the nuances of each stage of growth. Each client receives a customized playbook with services ranging from:
Ripston’s founders bring over 25 years of deep clinical trial and marketing expertise for B2B start-ups.
Amy Ripston, Founder & CEO of Ripston, has 17 years of experience in the pharmaceutical industry, with a passion for building brands and marketing organizations from the ground up. Over the last 9 years, Amy was the Vice President of Marketing for both 4G Clinical, a cutting-edge RTSM provider and Slope, a biospecimen lifecycle software provider. A driver of innovation in clinical trials, Amy founded the Biospecimen Management Consortium, a non-profit dedicated to driving sample excellence in clinical research, where she also currently serves as President.
Sabrina Fei, Founder, Growth Marketing & Technology Strategist of Ripston, has over a decade of experience in life sciences marketing. She has scaled multiple B2B start-ups through data-driven demand generation, marketing technology infrastructure, and tech-enabled growth systems. She specializes in aligning marketing with revenue outcomes, orchestrating lifecycle strategies that connect demand, customer experience, and personalization, and equipping vendors with scalable go-to-market models.
Founded in 2025, Ripston is a specialized B2B marketing agency dedicated to clinical trial start-ups. We combine deep industry and marketing expertise with AI-accelerated execution to help life sciences companies build authentic brands, optimize marketing operations, and achieve measurable growth. Our leadership brings decades of experience in clinical trial marketing, brand development, and growth strategy, uniquely positioning Ripston as a catalyst for start-ups navigating complex markets. Headquartered in Natick, Massachusetts, we partner with ambitious clinical trial vendors ready to transform bold ideas into unshakeable brands. Learn more at www.ripston.com.
Media Contact:
